MX2007012662A - Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib. - Google Patents
Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib.Info
- Publication number
- MX2007012662A MX2007012662A MX2007012662A MX2007012662A MX2007012662A MX 2007012662 A MX2007012662 A MX 2007012662A MX 2007012662 A MX2007012662 A MX 2007012662A MX 2007012662 A MX2007012662 A MX 2007012662A MX 2007012662 A MX2007012662 A MX 2007012662A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitor
- egfr
- growth factor
- factor receptor
- epidermal growth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Esta invencion describe un metodo para tratar o inhibir el cancer en un humano que tiene al menos uno de un E746-A750 eliminacion de exon 19 y/o una mutacion de punto exon 21 que comprende administrar a dicho humano gefitinib y/o iressa solo o en combinacion con otros agentes citotoxicos o agentes quimioterapeuticos y una cantidad efectiva del inhibidor de cinasa EGFR.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67128705P | 2005-04-14 | 2005-04-14 | |
PCT/US2006/012877 WO2006113151A2 (en) | 2005-04-14 | 2006-04-07 | Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007012662A true MX2007012662A (es) | 2008-04-04 |
Family
ID=36791648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007012662A MX2007012662A (es) | 2005-04-14 | 2006-04-07 | Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib. |
Country Status (19)
Country | Link |
---|---|
US (1) | US20060235046A1 (es) |
EP (1) | EP1871371A2 (es) |
JP (1) | JP2008536847A (es) |
KR (1) | KR20080002826A (es) |
CN (1) | CN101160129A (es) |
AR (1) | AR053357A1 (es) |
AU (1) | AU2006236940A1 (es) |
BR (1) | BRPI0610574A2 (es) |
CA (1) | CA2646257A1 (es) |
CR (1) | CR9415A (es) |
GT (1) | GT200600146A (es) |
IL (1) | IL186302A0 (es) |
MX (1) | MX2007012662A (es) |
NO (1) | NO20074722L (es) |
PE (1) | PE20061396A1 (es) |
RU (1) | RU2007134908A (es) |
TW (1) | TW200718421A (es) |
WO (1) | WO2006113151A2 (es) |
ZA (1) | ZA200708755B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ556673A (en) | 2005-02-03 | 2010-03-26 | Gen Hospital Corp | Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor |
BRPI0618042A2 (pt) | 2005-11-04 | 2011-08-16 | Wyeth Corp | usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
ES2835349T3 (es) | 2008-06-17 | 2021-06-22 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
WO2010017163A1 (en) * | 2008-08-04 | 2010-02-11 | Wyeth | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
KR101341876B1 (ko) * | 2008-09-05 | 2013-12-20 | 셀진 아빌로믹스 리서치, 인코포레이티드 | 비가역 인히비터 디자인을 위한 알고리즘 |
WO2010086382A1 (en) * | 2009-01-30 | 2010-08-05 | Pronota N.V. | Target for treatment of acute heart failure |
RU2011139363A (ru) | 2009-04-06 | 2013-05-20 | ВАЙЕТ ЭлЭлСи | Схема лечения рака молочной железы с использованием нератиниба |
EP2478361A4 (en) | 2009-09-16 | 2014-05-21 | Celgene Avilomics Res Inc | CONJUGATES AND INHIBITORS OF PROTEIN KINASE |
RU2012132473A (ru) | 2009-12-30 | 2014-02-10 | Селджин Авиломикс,Инк | Лиганд-направленная ковалентная модификация белка |
RU2746405C2 (ru) | 2014-08-29 | 2021-04-13 | Тес Фарма С.Р.Л. | ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ-ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ |
US9364469B1 (en) * | 2015-08-26 | 2016-06-14 | Macau University Of Science And Technology | Identification of a new AMPK activator for treatment of lung cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
RU2006106267A (ru) * | 2003-08-01 | 2006-07-27 | Уайт Холдингз Корпорейшн (Us) | Применение комбинации ингибитора киназы рецептора эпидермального фактора роста и цитотоксических средств для лечения и ингибирования рака |
US7399865B2 (en) * | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
CN102586431B (zh) * | 2004-03-31 | 2015-04-22 | 综合医院公司 | 测定癌症对表皮生长因子受体靶向性治疗反应性的方法 |
NZ556673A (en) * | 2005-02-03 | 2010-03-26 | Gen Hospital Corp | Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor |
-
2006
- 2006-04-07 BR BRPI0610574-2A patent/BRPI0610574A2/pt not_active IP Right Cessation
- 2006-04-07 MX MX2007012662A patent/MX2007012662A/es unknown
- 2006-04-07 KR KR1020077023472A patent/KR20080002826A/ko not_active Application Discontinuation
- 2006-04-07 CN CNA2006800123594A patent/CN101160129A/zh active Pending
- 2006-04-07 RU RU2007134908/14A patent/RU2007134908A/ru not_active Application Discontinuation
- 2006-04-07 AU AU2006236940A patent/AU2006236940A1/en not_active Abandoned
- 2006-04-07 JP JP2008506526A patent/JP2008536847A/ja not_active Withdrawn
- 2006-04-07 CA CA002646257A patent/CA2646257A1/en not_active Abandoned
- 2006-04-07 EP EP06740650A patent/EP1871371A2/en not_active Withdrawn
- 2006-04-07 WO PCT/US2006/012877 patent/WO2006113151A2/en active Application Filing
- 2006-04-10 TW TW095112747A patent/TW200718421A/zh unknown
- 2006-04-10 GT GT200600146A patent/GT200600146A/es unknown
- 2006-04-12 US US11/403,170 patent/US20060235046A1/en not_active Abandoned
- 2006-04-12 AR ARP060101468A patent/AR053357A1/es unknown
- 2006-04-17 PE PE2006000400A patent/PE20061396A1/es not_active Application Discontinuation
-
2007
- 2007-09-17 NO NO20074722A patent/NO20074722L/no not_active Application Discontinuation
- 2007-09-25 IL IL186302A patent/IL186302A0/en unknown
- 2007-10-04 CR CR9415A patent/CR9415A/es not_active Application Discontinuation
- 2007-10-12 ZA ZA200708755A patent/ZA200708755B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2008536847A (ja) | 2008-09-11 |
PE20061396A1 (es) | 2007-01-12 |
RU2007134908A (ru) | 2009-05-20 |
WO2006113151A3 (en) | 2007-01-11 |
TW200718421A (en) | 2007-05-16 |
BRPI0610574A2 (pt) | 2010-07-06 |
CA2646257A1 (en) | 2006-10-26 |
CR9415A (es) | 2008-01-21 |
ZA200708755B (en) | 2008-10-29 |
AR053357A1 (es) | 2007-05-02 |
IL186302A0 (en) | 2008-08-07 |
AU2006236940A1 (en) | 2006-10-26 |
CN101160129A (zh) | 2008-04-09 |
NO20074722L (no) | 2007-11-12 |
US20060235046A1 (en) | 2006-10-19 |
EP1871371A2 (en) | 2008-01-02 |
KR20080002826A (ko) | 2008-01-04 |
GT200600146A (es) | 2006-11-07 |
WO2006113151A2 (en) | 2006-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200718421A (en) | Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients | |
MXPA06001110A (es) | Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer. | |
AP1913A (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
MX2009009304A (es) | Inhibidores de cinasa pim y metodos para su uso. | |
IL180137A0 (en) | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer | |
IS2855B (is) | 4-anilínókínasólínafleiður sem andfjölgunarefni | |
PL1682126T3 (pl) | Podstawione benzazole i ich zastosowanie jako inhibitorów kinazy Raf | |
CY1112478T1 (el) | Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες | |
IL184791A (en) | Gaffitinib-Resistant Cancer Treatment Compounds A method to treat gafitinib-resistant cancer with an EGFR gene t790m using irreversible EGFR inhibitors | |
IL191832A (en) | Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors | |
TW200512205A (en) | Quinazoline derivatives | |
HUS1500018I1 (hu) | A Bruton-féle tirozin-kináz inhibitorai | |
RS48804A (en) | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers | |
HK1130794A1 (en) | Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors | |
MXPA06000915A (es) | Inhibidores de quinasa p-38. | |
IL201284A (en) | K3pi alpha pyridopyrimidinone inhibitor for use in combination with one or more therapeutic agents selected from Taxol, Rapamycin, Carboplatin and Arlutinib for cancer treatment | |
EP1781296A4 (en) | QUINAZOLINE DERIVATIVES, USE THEREOF IN THE TREATMENT OF THROMBOCYTHEMIA | |
NZ544719A (en) | Combination of mGluR2 antagonist and aChE inhibitor for treatment of acute and/or chronic neurological disorders | |
TNSN07263A1 (en) | Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them | |
PT2059246E (pt) | Composições terapêuticas que contêm um antagonista específico do receptor de endotelina e um inibidor de pde5 | |
MXPA05011858A (es) | Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico. | |
MX2007000360A (es) | Marcadores moleculares de pronostico. | |
HK1072012A1 (en) | 5-ht4 receptor antagonists for the treatment of heart failure | |
TNSN08512A1 (en) | Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists | |
TH85151B (th) | การยับยั้งรีเซพเตอร์ไคเนสของปัจจัยการเจริญเติบโตหนังกำพร้า (egfr) ในผู้ป่วยที่ดื้อต่อจีฟิทินิฟ |